Featured
FDA news: Top items in ophthalmology for 2024
December 27, 2024 1 min read Healio’s top FDA articles in ophthalmology this year included updates on the Vabsymo prefilled syringe, two new aflibercept biosimilars and an oral therapy for Stargardt disease. Check out 2024’s top FDA news below.
Continue Reading FDA news: Top items in ophthalmology for 2024
RETINA NEWS SPOTLIGHT
Alert: Alcon voluntarily recalls Systane Ultra PF lot due to potential fungal contamination
In response to a report of foreign material found in a sealed vial, Alcon Laboratories has initiated a voluntary recall of Lot 10101 of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count.Alcon evaluated a consumer complaint of foreign material observed inside a sealed…
Eyecare wrapped: Top stories from Modern Retina in 2024
In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ophthalmology, and retina conferences. Let’s look back on some of the top stories of the year as we gear up for an incredible 2025.GA and AMDAge-related macular…
Continue Reading Eyecare wrapped: Top stories from Modern Retina in 2024
Part 6: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?
This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.Video Transcript:Editor’s note: The below transcript has been lightly edited for clarity.Fatemah Rajaii, MD, PhD:I think it would be awesome if we had a way to…
Study: Thelazia callipaeda infection in a 41-year-old female patient
Thelaziasis, an ocular parasitic infection caused by Thelazia callipaeda, poses unique diagnostic and therapeutic challenges for ophthalmologists.This zoonotic disease, transmitted by Drosophilid flies, is associated with a spectrum of ocular symptoms ranging from mild irritation to severe inflammation. Here, we present a case of Thelazia callipaeda…
Continue Reading Study: Thelazia callipaeda infection in a 41-year-old female patient
Beyond VEGF: A Next-generation therapies aim to enhance vision and quality of life in neovascular AMD
VEGF-A therapy has revolutionized treatment and visual outcomes for patients with neovascular age-related macular degeneration (nAMD). Ranibizumab, the first anti–VEGF-A agent to be FDA approved, was introduced more than 18 years ago. Despite the introduction of additional nAMD therapies over the years, visual outcomes obtained have…
Early response of anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) management: microperimetry and optical coherence tomography (OCT) findings: a pilot study at national eye center of third world country
To evaluate early response of retinal sensitivity (RS) and retinal morphology in diabetic macular edema (DME) patients after intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.
Explore
Part 6: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?
This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.Video Transcript:Editor’s…
Study: Thelazia callipaeda infection in a 41-year-old female patient
Thelaziasis, an ocular parasitic infection caused by Thelazia callipaeda, poses unique diagnostic and therapeutic challenges for ophthalmologists.This zoonotic disease, transmitted by Drosophilid…
Continue Reading Study: Thelazia callipaeda infection in a 41-year-old female patient
Beyond VEGF: A Next-generation therapies aim to enhance vision and quality of life in neovascular AMD
VEGF-A therapy has revolutionized treatment and visual outcomes for patients with neovascular age-related macular degeneration (nAMD). Ranibizumab, the first anti–VEGF-A agent to…